CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes

Area of Science:

• Immunology
• Hepatology
• Virology

Background:

• CD56(+) T cells are prevalent in the liver and contribute to antiviral defense.
• The specific role of CD56(+) T cells in controlling hepatitis C virus (HCV) infection requires further elucidation.

Purpose of the Study:

• To investigate the non-cytolytic anti-HCV activity of primary CD56(+) T cells in human hepatocytes.
• To explore the underlying molecular mechanisms of CD56(+) T cell-mediated HCV inhibition.

Main Methods:

• Co-culture of HCV-infected hepatocytes with CD56(+) T cells or their supernatants.
• Assessment of HCV infectivity and replication.
• Analysis of interferon-gamma (IFN-γ) and IFN-γ receptor involvement.
• Evaluation of the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway and interferon regulatory factors (IRFs) expression.
• Measurement of endogenous IFN-α/β, miR-122, and miR-196a levels.

Main Results:

• CD56(+) T cells and their supernatants significantly inhibited HCV infectivity and replication in hepatocytes.
• Anti-HCV activity was largely blocked by antibodies to IFN-γ or its receptor.
• CD56(+) T cell supernatants activated the JAK/STAT pathway, enhanced IRF expression, and induced endogenous IFN-α/β in hepatocytes.
• Treatment with CD56(+) T cell supernatants reduced levels of the pro-viral miR-122 and increased anti-viral miR-196a.

Conclusions:

• CD56(+) T cells demonstrate significant non-cytolytic anti-HCV activity in vitro.
• The mechanism involves IFN-γ signaling, JAK/STAT pathway activation, and modulation of cellular microRNAs.
• These findings highlight a crucial role for CD56(+) T cells in the innate immune defense against HCV infection at cellular and molecular levels.